

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

January 31, 2025

John Yu Chief Executive Officer Kairos Pharma, LTD. 2355 Westwood Blvd., #139 Los Angeles, CA 90064

> Re: Kairos Pharma, LTD. Registration Statement on Form S-1 Filed January 29, 2025 File No. 333-284569

Dear John Yu:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Megan J. Penick